PMID: 16517412Mar 7, 2006Paper

Desmopressin and other synthetic vasopressin analogues in cancer treatment

Bulletin du cancer
Daniel E GomezDaniel F Alonso

Abstract

Desmopressin (DDAVP) is a well tolerated and convenient haemostatic agent that can be used in a number of clinical conditions with bleeding diathesis. It has several effects on the haemostatic system, causing endogenous release of coagulation factor VIII, von Willebrand factor and tissue-type plasminogen activator, among others. In this review we present a growing body of evidence showing that DDAVP treatment may impair spread of cancer cells and contribute to encapsulation of tumour tissue. Our data in preclinical animal models suggest a potential application of DDAVP in the perioperative management of aggressive solid tumours. Novel vasopressin analogues with improved antitumor effects are currently in development.

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

European Journal of Anaesthesiology. Supplement
S R Lethagen
Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie
C B Cameron, N Kobrinsky
Journal of Thrombosis and Haemostasis : JTH
J E Kaufmann, U M Vischer
© 2021 Meta ULC. All rights reserved